secwatch / observer
8-K filed November 15, 2023, 6:59 PM ET ticker ALGS CIK 0001799448
leadership confidence high sentiment negative materiality 0.60

Aligos Therapeutics President and Board member Leonid Beigelman resigns

Aligos Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leonid Beigelman

President
ALGS · Aligos Therapeutics, Inc.
Effective
2023-12-01
Filed
November 15, 2023, 6:59 PM ET
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.
Departed

Leonid Beigelman

Member of the Board of Directors
ALGS · Aligos Therapeutics, Inc.
Effective
2023-11-09
Filed
November 15, 2023, 6:59 PM ET
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leonid Beigelman resigned as President at Aligos Therapeutics, Inc..

Action
resigned
Role
President
Exact text from the filing
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Leonid Beigelman resigned as Member of the Board of Directors at Aligos Therapeutics, Inc..

Action
resigned
Role
Member of the Board of Directors
Exact text from the filing
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.
View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-277877
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.